May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Inhibition of Experimental Choroidal Neovascularization by the VEGF Receptor Inhibitor Pazopanib (GW786034B)
Author Affiliations & Notes
  • Y. Yafai
    University of Leipzig, Leipzig, Germany
  • M. Niemeyer
    University of Leipzig, Leipzig, Germany
  • T. Yasukawa
    University of Leipzig/Nagoya City University, Leipzig, Germany
  • A. Nishiwaki
    University of Leipzig/Nagoya City University, Leipzig, Germany
  • P. Wiedemann
    University of Leipzig, Leipzig, Germany
  • A. G. King
    GlaxoSmithKline, Collegeville, Pennsylvania
  • W. Eichler
    University of Leipzig, Leipzig, Germany
  • Footnotes
    Commercial Relationships  Y. Yafai, financial support, F; M. Niemeyer, None; T. Yasukawa, None; A. Nishiwaki, None; P. Wiedemann, None; A. G. King, None; W. Eichler, financial support, F.
  • Footnotes
    Support  GlaxoSmithKline, Collegeville PA, USA
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 534. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Y. Yafai, M. Niemeyer, T. Yasukawa, A. Nishiwaki, P. Wiedemann, A. G. King, W. Eichler; Inhibition of Experimental Choroidal Neovascularization by the VEGF Receptor Inhibitor Pazopanib (GW786034B). Invest. Ophthalmol. Vis. Sci. 2008;49(13):534.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Inhibition of vascular endothelial growth factor (VEGF) signaling has shown great promise for the treatment of ocular neovascular disease. Current anti-VEGF therapies, while efficacious, require dosing by frequent intravitreal injections that are inconvenient for patients. However, VEGF signaling inhibitors demonstrating more convenient dosing regimens could lead to increased treatment options for neovascular ocular diseases, such as wet form of age-related macular degeneration and diabetic macular edema. Pazopanib (GW786034B) is a potent multi-targeted tyrosine kinase inhibitor that antagonizes receptors for VEGF, PDGF, and stem cell growth factor. Here we describe the assessment of this drug in a well-established model of ocular neovascularization following topical administration via eye drops.

Methods: : Pazopanib (GW786034B), was dosed daily at 5 mg/ml for one week by topical administration in a rat model of laser induced choroidal neovascularization (CNV). Before and after the treatment period areas of CNV lesions were quantitated using fluorescence angiography, and the thickness of CNV complexes was determined histologically.

Results: : The intensity of fluorescein leakage from the photocoagulated lesions decreased significantly after pazopanib (GW786034B) treatment. Moreover, the thickness of the lesions was significantly reduced in eyes which received pazopanib (GW786034B) topically.

Conclusions: : Topical dosing of pazopanib (GW786034B) effectively inhibits CNV in a rat model of CNV. These data suggest that pazopanib (GW786034B) and/ or compounds of this class may prove useful for the treatment of a variety of ocular neovascular diseases using a convenient topical dosing regimen.

Keywords: age-related macular degeneration • choroid: neovascularization • laser 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×